Holen Sie sich die Stockscreener-App
15.10
1.65%
0.245
Schlusskurs vom Vortag:
$14.85
Offen:
$14.97
24-Stunden-Volumen:
562.16K
Relative Volume:
0.63
Marktkapitalisierung:
$942.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.71M
KGV:
-12.65
EPS:
-1.1935
Netto-Cashflow:
$-54.12M
1W Leistung:
+4.32%
1M Leistung:
+41.74%
6M Leistung:
+52.94%
1J Leistung:
+326.41%
1-Tages-Spanne:
$14.41
$15.22
1-Wochen-Bereich:
$13.53
$15.86
52-Wochen-Spanne:
$3.52
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
15.10 | 976.83M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
523.88 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.87 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.59 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | Jefferies | Buy |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
Cantor Fitzgerald reiterates Design Therapeutics stock rating - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com - Investing.com Nigeria
Design Therapeutics begins dosing DM1 drug in phase 1 trial - Investing.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - The Manila Times
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2000 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark - marketscreener.com
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Sahm
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN) - TradingView
Design Therapeutics, Inc. Actuals & Estimates (BOATS:DSGN) - TradingView
DSGN Forecast — Price Target — Prediction for 2027 - TradingView
DSGN News | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Design Therapeutics, Inc. (DSGN) is up 6.92% in one week: What you should know - MSN
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts - Seeking Alpha
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DSGN Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesRevenue Warning Signal - dars.gov.et
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - Business Wire
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics Inc (DSGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com
Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan
[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan
Director at Design Therapeutics (DSGN) awarded 30,000 stock options - Stock Titan
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire
DSGN Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineSubscription Growth Report - newsline.com
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):